PCA
NBIX icon

Pallas Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Pallas Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Sell
12,133
-4,650
-28% -$617K 0.06% 234
2025
Q4 		$2.38M Buy
16,783
+1,270
+8% +$184K 0.08% 195
2025
Q3 		$2.18M Buy
15,513
+6,120
+65% +$829K 0.08% 196
2025
Q2 		$1.18M Buy
9,393
+6,793
+261% +$779K 0.05% 296
2025
Q1 		$288K Sell
2,600
-5,073
-66% -$643K 0.01% 596
2024
Q4 		$1.05M Buy
7,673
+1,225
+19% +$152K 0.04% 226
2024
Q3 		$745K Buy
6,448
+3,350
+108% +$459K 0.03% 276
2024
Q2 		$447K Buy
3,098
+647
+26% +$88.7K 0.02% 329
2024
Q1 		$338K Buy
+2,451
New +$335K 0.01% 342

Other funds holding NBIX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return